| Name | Title | Contact Details |
|---|---|---|
Rama Donepudi |
Chief Information Officer (CIO), Global Nutrition at Reckitt | Profile |
Filippo Catalano |
Chief Information and Digitisation Officer | Profile |
Magdalena Skorupa |
Director of Cyber Risk and Compliance | Profile |
At Symbria, we unite passion, insight, and performance to help senior-living and post-acute providers build sustainable success. We don`t make this commitment lightly, understanding full well how challenging this goal is to achieve in today`s demanding, highly competitive environment. Every service we provide – from therapy to pharmacy to wellness to benchmarking – is thoughtfully developed and conscientiously implemented to amplify your ability to effectively and cost-efficiently meet the needs of the residents and patients your community serves.
OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.
Brotoloc Inc is a Eau Claire, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon, and breast cancers. In early 2014, Metamark plans to commercialize ProMark™—its prostate cancer prognostic test—through its Cambridge, Massachusetts CLIA-certified laboratory. For more information, please visit the company's Website at www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.
BRI Biopharmaceutical Research Inc is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.